Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Rating of "Moderate Buy" by Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $11.80.

A number of brokerages recently commented on CMPX. Leerink Partners cut Compass Therapeutics from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. Leerink Partnrs downgraded Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, November 15th. D. Boral Capital reaffirmed a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th.

Compass Therapeutics Stock Performance

NASDAQ CMPX traded up $0.10 during trading hours on Friday, reaching $2.60. 1,398,032 shares of the company's stock were exchanged, compared to its average volume of 3,664,826. The company has a market capitalization of $357.73 million, a price-to-earnings ratio of -7.03 and a beta of 0.92. Compass Therapeutics has a one year low of $0.76 and a one year high of $2.70. The company's 50-day moving average is $1.61 and its two-hundred day moving average is $1.48.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. Research analysts predict that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Trading of Compass Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Rovin Capital UT ADV acquired a new stake in Compass Therapeutics in the third quarter valued at approximately $25,000. Intech Investment Management LLC purchased a new position in Compass Therapeutics during the third quarter worth about $30,000. XTX Topco Ltd purchased a new position in shares of Compass Therapeutics in the 3rd quarter worth $37,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Compass Therapeutics in the second quarter worth about $41,000. Finally, SG Americas Securities LLC grew its stake in shares of Compass Therapeutics by 16.6% during the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company's stock valued at $71,000 after acquiring an additional 5,515 shares in the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.